Pfizer has agreed to pay $330 million upfront for exclusive rights to three experimental cell-therapy programs from Starna Therapeutics, expanding the drugmaker’s work in autoimmune disease, RNA-based medicines and targeted delivery technologies.
The agreement covers development, manufacturing and commercialization of the programs outside Greater China. All three are at the pre-investigational new drug, or pre-IND, stage, meaning they have not entered human clinical trials. Pfizer will lead clinical development and manufacture products for initial clinical studies at its facilities in the United States.
Deal terms and development rights
In addition to the upfront payment, Starna could receive as much as $2.3 billion in development and commercial milestone payments. The agreement also provides for royalties on net sales of products that eventually receive approval. The financial terms do not represent an approval or a guarantee that any of the programs will reach the market.
| Element | Terms |
|---|---|
| Partner | Starna Therapeutics |
| Programs | Three experimental in vivo CAR-T programs |
| Target area | Autoimmune diseases |
| Upfront payment | $330 million |
| Potential milestones | Up to $2.3 billion, plus royalties on net sales |
| Territory | Outside Greater China |
| Development stage | Pre-IND; not yet tested in human clinical trials |
Starna’s programs use an in vivo CAR-T approach, which is designed to generate CAR-T cells inside the body rather than relying only on a process in which cells are prepared outside the patient. The technology combines RNA therapeutics with targeted lipid nanoparticle delivery systems intended to transport genetic medicines to specific tissues, according to the agreement details.
“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short.” — Michael Vincent, M.D., Ph.D., Pfizer’s chief inflammation and immunology officer
Pfizer will receive rights to use Starna’s proprietary in vivo CAR-T technology in both inflammation and immunology and oncology. The companies also included options covering additional research programs and a possible expansion of Pfizer’s rights into Greater China.
Why the research remains early
The programs’ pre-IND status places them before human clinical testing. Before a candidate can enter trials, its developers must advance the research and development work needed for an investigational new drug submission. The agreement therefore gives Pfizer access to a platform and development programs, rather than a late-stage medicine with established safety or effectiveness in patients.
- Pfizer will direct clinical development.
- Initial clinical-trial products will be manufactured at Pfizer’s U.S. facilities.
- Starna’s technology will be available to Pfizer for research in autoimmune disease and cancer.
The deal adds to Pfizer’s research activity in cell therapies and RNA-based medicines while giving Starna access to Pfizer’s development and manufacturing capabilities. Any future clinical results, regulatory filings or product approvals would be separate milestones from the agreement announced on November 18, 2026.